Medison Expands Global Reach with Appointment of Francis Wan as APAC Head

Medison, a pioneering innovator in the biopharmaceutical sector, has recently made headlines with the announcement of Francis Wan's appointment as Vice President and General Manager for the Asia Pacific (APAC) region. This move is seen as a significant stride in Medison's commitment to enhancing its global commercialization platform, particularly for breakthrough therapies that are often inaccessible in various markets.

As a company, Medison has firmly established itself as a leader in its unique approach, providing a unified commercialization framework that supports the introduction of cutting-edge treatments on an international scale. With Wan's extensive background in biopharmaceuticals—spanning over two decades, including high-profile roles at Biogen and MSD China—his leadership is expected to catalyze Medison's development and operational strategies across the APAC region, a crucial area for growth.

Medison’s Global Leadership Team recognized Wan's capabilities, emphasizing that his expertise in rare diseases and oncology will be instrumental in overcoming the barriers that prevent many patients in APAC from accessing breakthrough treatments. During his tenure at Biogen as President for the APAC region, Wan was instrumental in advancing innovative therapies and implementing sustainable access models. Recently, he noted, “Across APAC, breakthrough therapies are still out of reach for many patients, leaving a vast and diverse population with significant unmet needs. Through Medison's platform, we have a unique opportunity to change this reality.”

This sentiment is echoed by Meir Jakobsohn, Medison's Founder and Executive Chairman, who stated that Medison was built on the principle that every patient deserves timely access to essential therapies. He described Wan's appointment as indicative of the company’s ongoing investment in the APAC region, which poses both immense challenges and opportunities for growth.

Furthermore, Gil Gurfinkel, the CEO of Medison, underlined the importance of Wan’s appointment in furthering their global growth ambitions, stating this addition aligns with their goal of expanding their reach and maintaining their status as a leading commercialization company in international markets. Gurfinkel's confidence in Wan's ability to facilitate access to vital therapies highlights the critical role leadership plays in navigating the complex healthcare landscapes prevalent in regional markets.

Victor Papamoniodis, Medison's Chief Commercial Officer, echoed a similar sentiment, pointing out that Wan’s proven track record in establishing and scaling biopharma operations positions him as a key player in enhancing Medison’s capabilities in APAC. As the area becomes increasingly vital in the larger context of global health, Medison remains focused on expanding its partnerships and improving the delivery of life-altering treatments.

With a promising strategy laid down, Medison's commitment to tackling one of the foremost challenges in the pharmaceutical industry—enabling access to breakthrough therapies for patients with severe diseases in international markets—positions them as a vital partner for innovative biotech firms. Their affiliate-like model integrates commercial, medical, and operational capacities across diverse geographies, ensuring that more patients gain rapid access to transformative treatments.

In summary, the appointment of Francis Wan marks a pivotal moment for Medison, as they strive to enhance their footprint within the APAC region. The move is a significant step towards fulfilling their mission of awarding every patient, regardless of their location, the chance to benefit from innovative therapies. The health care sector, with its intricate dynamics, demands visionary leadership, and Medison's forward-thinking strategy seems well positioned to meet these challenges head-on.

To learn more about Medison and their initiatives, visit Medison's website.